InvestorsObserver
Sign Up Login

ALBO Albireo Pharma Inc

$20.05 $0.54 (2.77%)
Add to Watchlist Compare
Overall

ALBO Stock Analysis Overview

What this means: InvestorsObserver gives Albireo Pharma Inc (ALBO) an overall rank of 34, which is below average. Albireo Pharma Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 34 means that 66% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

ALBO Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

ALBO Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

ALBO Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

ALBO Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

ALBO Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

ALBO Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

ALBO Stock Analysis Overview

What this means: InvestorsObserver gives Albireo Pharma Inc (ALBO) an overall rank of 34, which is below average. Albireo Pharma Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 34 means that 66% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full ALBO report

ALBO Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

ALBO Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

ALBO Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

ALBO Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

ALBO Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

ALBO Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Albireo Pharma Inc (ALBO) Analyst Forecast

ALBO Price, Volume, Earnings, and Dividend Date

  • Last Price $20.05
  • Previous Close $19.51
  • Change $0.54
  • Open $19.19
  • Volume 310,204
  • Avg. Volume (100-day) 379,658
  • Market Cap 393,230,805
  • Days Range 19 - 20.1
  • 52-week Range 16.02 - 37.63
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 11/03/22
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 0.629
  • PEG Ratio —

Albireo Pharma Inc (ALBO) Company Description

Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.

Albireo Pharma Inc (ALBO) Stock Chart

View Interactive ALBO chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Biotechnology

Company Price
Logicbio Therapeutics Inc (LOGC) (LOGC) $2.03
Ardelyx Inc (ARDX) (ARDX) $1.51
Liquidia Corp (LQDA) (LQDA) $5.58
Axsome Thera (AXSM) (AXSM) $46.08
Satsuma Pharmaceuticals Inc (STSA) (STSA) $5.18
Minerva Neuroscie (NERV) (NERV) $10.15
G1 Therapeutics Inc (GTHX) (GTHX) $13.24
Wave Life Sci Ord Sh (WVE) (WVE) $3.66
Savara Inc (SVRA) (SVRA) $1.49
Capricor Therap (CAPR) (CAPR) $6.10